Abstract
Stevens-Johnson syndrome (SJS) is an uncommon life-threatening skin disease, generally induced by drugs. Extracutaneous manifestations of the syndrome can occur, and may involve the conjunctiva, buccal mucosa, gastrointestinal and genitourinary tracts. Cholestatic hepatitis has been rarely described in SJS.
A 29-year-old woman was admitted with generalized cutaneous eruption. A self-medication with paracetamol had been started three days earlier. Clinical signs and skin biopsy were consistent with SJS. Five days later, the patient developed jaundice. Serial liver function tests showed rising transaminases, bilirubin, alkaline phosphatase and γ-glutamyl transferase. Liver biopsy was performed and was consistent with the diagnosis of drug-induced cholestatic hepatitis. Adequate supportive care was provided to the patient. Skin lesions disappeared within two weeks. Jaundice disappeared progressively, and liver tests returned to normal.
Herein, we report the first case of SJS associated with cholestatic hepatitis after ingestion of therapeutic doses of paracetamol.
Keywords: Cholestasis, drug-induced, eruption, hepatitis, paracetamol, Stevens-Johnson syndrome.
Current Drug Safety
Title:Paracetamol-Induced Stevens Johnson Syndrome and Cholestatic Hepatitis
Volume: 10 Issue: 2
Author(s): Raoudha Slim, Neila Fathallah, Amina Aounallah, Mehdi Ksiaa, Badreddine Sriha, Rafiaa Nouira and Chaker Ben Salem
Affiliation:
Keywords: Cholestasis, drug-induced, eruption, hepatitis, paracetamol, Stevens-Johnson syndrome.
Abstract: Stevens-Johnson syndrome (SJS) is an uncommon life-threatening skin disease, generally induced by drugs. Extracutaneous manifestations of the syndrome can occur, and may involve the conjunctiva, buccal mucosa, gastrointestinal and genitourinary tracts. Cholestatic hepatitis has been rarely described in SJS.
A 29-year-old woman was admitted with generalized cutaneous eruption. A self-medication with paracetamol had been started three days earlier. Clinical signs and skin biopsy were consistent with SJS. Five days later, the patient developed jaundice. Serial liver function tests showed rising transaminases, bilirubin, alkaline phosphatase and γ-glutamyl transferase. Liver biopsy was performed and was consistent with the diagnosis of drug-induced cholestatic hepatitis. Adequate supportive care was provided to the patient. Skin lesions disappeared within two weeks. Jaundice disappeared progressively, and liver tests returned to normal.
Herein, we report the first case of SJS associated with cholestatic hepatitis after ingestion of therapeutic doses of paracetamol.
Export Options
About this article
Cite this article as:
Slim Raoudha, Fathallah Neila, Aounallah Amina, Ksiaa Mehdi, Sriha Badreddine, Nouira Rafiaa and Salem Ben Chaker, Paracetamol-Induced Stevens Johnson Syndrome and Cholestatic Hepatitis, Current Drug Safety 2015; 10 (2) . https://dx.doi.org/10.2174/1574886309666140827122735
DOI https://dx.doi.org/10.2174/1574886309666140827122735 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Suramin: Clinical Uses and Structure-Activity Relationships
Mini-Reviews in Medicinal Chemistry A Case Report of Antitubercular Drugs Induced Exanthematous Reaction Complicated by Acute Onset Levofloxacin Induced Toxic Epidermal Necrolysis (TEN)
Current Drug Safety Current Issues in the Management of Pediatric Functional Abdominal Pain
Reviews on Recent Clinical Trials Cellular Tests in the Diagnosis of Drug Hypersensitivity
Current Pharmaceutical Design Neuro-Inflammatory Mechanisms in Developmental Disorders Associated with Intellectual Disability and Autism Spectrum Disorder: A Neuro- Immune Perspective
CNS & Neurological Disorders - Drug Targets The Emerging Pharmacology of TRPM8 Channels: Hidden Therapeutic Potential Underneath a Cold Surface
Current Pharmaceutical Biotechnology Hematopoietic Transplants for Disease Suppression and Cure in Type 1 Diabetes
Current Stem Cell Research & Therapy Synthesis and Bioactivity of (R)-Ricinoleic Acid Derivatives: A Review
Current Medicinal Chemistry Role of Topical Calcineurin Inhibitors on Atopic Dermatitis of Children
Current Medicinal Chemistry PASylation as a Powerful Technology for Improving the Pharmacokinetic Properties of Biopharmaceuticals
Current Drug Delivery How do Glial Cells Contribute to Motor Control?
Current Pharmaceutical Design Novel Approaches for RNA Interference and their Application in Cancer Therapy
Current Pharmacogenomics Prevention of Gestational Diabetes Mellitus (GDM) and Probiotics: Mechanism of Action: A Review
Current Diabetes Reviews Harnessing Phage Display for the Discovery of Peptide-Based Drugs and Monoclonal Antibodies
Current Medicinal Chemistry Transglutaminases as Targets for Pharmacological Inhibition
Mini-Reviews in Medicinal Chemistry Cilostazol in the Management of Atherosclerosis
Current Vascular Pharmacology Polycystic Ovary Syndrome as a Proinflammatory State: The Role of Adipokines
Current Pharmaceutical Design Radioprotective Effect of Gliclazide as an Anti-Hyperglycemic Agent Against Genotoxicity Induced by Ionizing Radiation on Human Lymphocytes
Cardiovascular & Hematological Agents in Medicinal Chemistry Renal Protective Effect of Metabolic Therapy in Patients with Coronary Artery Disease and Diabetes: From Bench to Bed Side
Current Pharmaceutical Design Transductional Targeting with Recombinant Adenovirus Vectors
Current Gene Therapy